By Colin Kellaher
XOMA Royalty's top finance executive, Thomas Burns, is leaving the biotechnology royalty aggregator to pursue other opportunities.
XOMA on Monday said Jeffrey Trigilio, who most recently served as chief financial and operating officer of Obsidian Therapeutics, will succeed Burns as chief financial officer of the Emeryville, Calif., company.
Burns, who joined XOMA in August 2006, has been senior vice president of finance and finance chief since March 2017.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 12, 2026 07:50 ET (12:50 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.